Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEA-targeted CAR-T in advanced solid tumors
NCT06126406Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of C-13-60 in gastric cancer (GC), colon cancer, rectal cancer and 5 more (2 arms), sponsored by Chongqing Precision Biotech. Primary endpoints: Incidence of Treatment-associated Adverse Events at 1 month and Obtained the recommended dose and infusion regimen of CAR-T cells at 28 days. Started Nov 2023; status: recruiting.
02
Drugs
C-13-60
03
Conditions
gastric cancer (GC)colon cancerrectal cancerbreast cancerlung cancer
Beyond the preview
Go deeper on NCT06126406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126406.